Atea Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
AVIR$4.20-4.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Operating expenses | ||||
| Research and development | $27,091 | $38,347 | $96,375 | $100,206 |
| General and administrative | 6,922 | 7,220 | 20,745 | 25,747 |
| Total operating expenses | 34,013 | 45,567 | 117,120 | 125,953 |
| Loss from operations | (34,013) | (45,567) | (117,120) | (125,953) |
| Interest income and other, net | 1,889 | 3,714 | 6,697 | 13,077 |
| Loss before income taxes | (32,124) | (41,853) | (110,423) | (112,876) |
| Income tax expense | (38) | (196) | (112) | (606) |
| Net loss | $(32,162) | $(42,049) | $(110,535) | $(113,482) |
| Other comprehensive loss | ||||
| Unrealized gain (loss) on available-for-sale investments | 23 | 201 | (247) | 5 |
| Comprehensive loss | $(32,139) | $(41,848) | $(110,782) | $(113,477) |
| Net loss per share — basic and diluted | $(0.40) | $(0.53) | $(1.38) | $(1.37) |
| Weighted-average number of common shares — basic and diluted | 80,224,959 | 79,052,154 | 79,828,321 | 82,623,806 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.